Last reviewed · How we verify
Optimer Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) — Portfolio Competitive Intelligence Brief
0 marketed
0 filed
2 Phase 3
0 Phase 2
0 Phase 1
Live · 30-min refresh
Portfolio leaders (marketed + Phase 3 / filed)
| Drug | Generic | Phase | Class | Target | Area | First approval |
|---|---|---|---|---|---|---|
| Matching Placebo to Fidaxomicin | Matching Placebo to Fidaxomicin | phase 3 | Infectious Disease | |||
| PAR-101/OPT-80 | PAR-101/OPT-80 | phase 3 | Non-systemic antibiotic; bacterial RNA polymerase inhibitor | Bacterial RNA polymerase (C. difficile) | Infectious Disease |
Therapeutic area mix
- Infectious Disease · 2
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Competitive overlap (companies sharing drug classes)
Subscribe to ongoing alerts
Every new pipeline event for Optimer Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA):
- Optimer Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) pipeline updates — RSS
- Optimer Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) pipeline updates — Atom
- Optimer Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) pipeline updates — JSON
Cite this brief
Drug Landscape (2026). Optimer Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/optimer-pharmaceuticals-llc-a-subsidiary-of-merck-co-inc-rahway-new-jersey-usa. Accessed 2026-05-16.